The THRIVE-132 study is determining the safety and efficacy of a single dose of inclacumab, an investigational therapy, as a possible treatment to prevent readmission to the hospital for a vaso-occlusive crises (VOCs) in individuals with sickle cell disease.
6 United States sites
3 Turkey sites
2 Lebanon sites
1 Italy site
1 Kenya site
1 Omanc site
> 12 Years
All types of SCD
3
The Hibiscus Study is enrolling adults and adolescents 12 to 65 years old with a clinical diagnosis of SCD.
1 United States site
1 Europe site
1 Canada site
12 - 65 Years
All types of SCD
2/3
The THRIVE-131 study will evaluate the safety and efficacy of an investigational therapy called inclacumab to decrease vaso-occlusive crises in participants with sickle cell disease.
14 USA sites
4 Kenya sites
3 France sites
3 Italy sites
3 Turkey sites
2 Lebanon sites
1 Brazil site
1 Germany site
1 Saudi Arabia site
1 Oman site
1 Tanzania site
1 United Kingdom site
> 12 Years
SCD type SS, SCD type SC, SCD type Sβ0 thalassemia, SCD type Sβ+ thalassemia
3
To identify treatments that do not rely only on opioids or other medications.
